Switch theme
Sign up to access all valuation multiples
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
2022
69
Last FY Revenue n/a
LTM EBITDA -$105M
$23.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rapport Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$105M.
In the most recent fiscal year, Rapport Therapeutics achieved revenue of n/a and an EBITDA of -$82.2M.
Rapport Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rapport Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$105M | XXX | -$82.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$105M | XXX | -$83.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$99.1M | XXX | -$78.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rapport Therapeutics's stock price is $8.
Rapport Therapeutics has current market cap of $301M, and EV of $23.4M.
See Rapport Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.4M | $301M | XXX | XXX | XXX | XXX | $-3.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rapport Therapeutics has market cap of $301M and EV of $23.4M.
Rapport Therapeutics's trades at n/a EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Rapport Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rapport Therapeutics has a P/E ratio of -3.0x.
See valuation multiples for Rapport Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $301M | XXX | $301M | XXX | XXX | XXX |
| EV (current) | $23.4M | XXX | $23.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -3.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRapport Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Rapport Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rapport Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rapport Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rapport Therapeutics acquired XXX companies to date.
Last acquisition by Rapport Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Rapport Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rapport Therapeutics founded? | Rapport Therapeutics was founded in 2022. |
| Where is Rapport Therapeutics headquartered? | Rapport Therapeutics is headquartered in United States of America. |
| How many employees does Rapport Therapeutics have? | As of today, Rapport Therapeutics has 69 employees. |
| Who is the CEO of Rapport Therapeutics? | Rapport Therapeutics's CEO is Mr. Abraham N. Ceesay, M.B.A.. |
| Is Rapport Therapeutics publicy listed? | Yes, Rapport Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Rapport Therapeutics? | Rapport Therapeutics trades under RAPP ticker. |
| When did Rapport Therapeutics go public? | Rapport Therapeutics went public in 2024. |
| Who are competitors of Rapport Therapeutics? | Similar companies to Rapport Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rapport Therapeutics? | Rapport Therapeutics's current market cap is $301M |
| Is Rapport Therapeutics profitable? | Yes, Rapport Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rapport Therapeutics? | Rapport Therapeutics's last 12 months EBITDA is -$105M. |
| What is the current EV/EBITDA multiple of Rapport Therapeutics? | Current EBITDA multiple of Rapport Therapeutics is -0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
